Follow
International Journal of Current Microbiology and Applied Sciences (IJCMAS)
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2018 - IJCMAS--ICV 2018: 95.39 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2020) [Effective from January 1, 2020]For more details click here

Login as a Reviewer

Indexed in



National Academy of Agricultural Sciences (NAAS)
NAAS Score: *5.38 (2020)
[Effective from January 1, 2020]
For more details click here

ICV 2018: 95.39
Index Copernicus ICI Journals Master List 2018 - IJCMAS--ICV 2018: 95.39
For more details click here

See Guidelines to Authors
Current Issues

Original Research Articles

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcmas@gmail.com / submit@ijcmas.com
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2018: 95.39
NAAS RATING 2020: 5.38

Int.J.Curr.Microbiol.App.Sci.2018.7(3): 2252-2260
DOI: https://doi.org/10.20546/ijcmas.2018.703.265


Impact of Erlotinib and Metformin Administration on Pharmacokinetics of Meloxicam in SCID Mice
S.D. Patel1*, U.D. Patel2, K.A. Sadariya3, S.K. Bhavsar3 and A.M. Thaker3
1Zydus Research Centre, Cadila Healthcare Ltd., Ahmedabad, India
2College of Veterinary Science and Animal Husbandry, Junagadh Agricultural University, Junagadh, India
3College of Veterinary Science and Animal Husbandry, Anand Agricultural University, Anand, India
*Corresponding author
Abstract:

Pharmacokinetics of meloxicam was studied following its single dose intraperitoneal administration alone and administered with erlotinib and/or metformin in SCID mice. The plasma concentration of meloxicam was assayed by LC-MS/MS. Following administration of meloxicam as single drug in male SCID mice, the mean values of observed peak plasma drug concentration (Cmax), time of maximum concentration (Tmax), area under plasma drug concentration-time curve (AUC0-ï‚¥), volume of distribution (Vz), half-life (t½) and total body clearance (Cl) were 45715.22 ± 3343.07 ng/mL, 0.40 ± 0.09 h, 123999.94 ± 4181.79 ng.h/mL, 873.90 ± 59.61 ml, 3.79 ± 0.34 h and162.24 ± 5.67 ml/h, respectively. When erlotinib and/or metformin were administered with meloxicam in SCID mice, significant alterationin pharmacokinetic parameters of meloxicam were observed. Thus, pharmacovigilance should be followed for the concomitant administration of these drugs for prolong period. However, clinical pharmacokinetic interaction of these drugs in human needs to be evaluated.


Keywords: Pharmacokinetic, Meloxicam, Erlotinib, Metformin, SCID mice
Download this article as Download

How to cite this article:

Patel, S.D., U.D. Patel, K.A. Sadariya, S.K. Bhavsar and Thaker, A.M. 2018. Impact of Erlotinib and Metformin Administration on Pharmacokinetics of Meloxicam in SCID Mice.Int.J.Curr.Microbiol.App.Sci. 7(3): 2252-2260. doi: https://doi.org/10.20546/ijcmas.2018.703.265